Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Depreciation & Amortization (CF) (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $52620.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) rose 9.01% year-over-year to $52620.0, compared with a TTM value of $207518.0 through Sep 2025, up 14.4%, and an annual FY2024 reading of $189056.0, up 14.07% over the prior year.
  • Depreciation & Amortization (CF) was $52620.0 for Q3 2025 at BioRestorative Therapies, roughly flat from $52748.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $52748.0 in Q2 2025 and bottomed at $21496.0 in Q4 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $37978.6, with a median of $41526.0 recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) plummeted 44.7% in 2021, then soared 51.29% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $21496.0 in 2021, then surged by 47.91% to $31794.0 in 2022, then skyrocketed by 34.34% to $42713.0 in 2023, then increased by 17.92% to $50369.0 in 2024, then grew by 4.47% to $52620.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for BRTX at $52620.0 in Q3 2025, $52748.0 in Q2 2025, and $51781.0 in Q1 2025.